In a retrospective study on the prognosis of immunotherapy with ICIs for hepatocellular carcinoma (HCC), the researchers found that the identification of predictive biomarkers of response (such as TMB and PD-L1) could effectively help patients during immunotherapy, suggesting that the targeted study of prognostic biomarkers of immunotherapy has broad prospects (23). The gene discussed is CD274; the disease is hepatocellular carcinoma.